Ciclosporin ophthalmic - Altacor

Drug Profile

Ciclosporin ophthalmic - Altacor

Alternative Names: Cyclosporin A - OphthalmoPharma; Cyclosporin A prodrug - OphthalmoPharma; OPPH 088

Latest Information Update: 10 Aug 2015

Price : $50

At a glance

  • Originator CIS Pharma
  • Developer Altacor
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Dry eyes; Keratoplasty rejection; Uveitis

Most Recent Events

  • 04 Aug 2015 Altacor has been acquired by Esperante Ventures
  • 26 Jul 2011 Altacor acquires Ciclosporin opthalmic from OpthalmoPharma
  • 26 Jul 2011 Clinical trials in Dry eyes in England (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top